Effect of telbivudine on serum IL-18,IL-12, IL-37 and TNF-αlevels in patients with HBV-related hepatocirrhosis
- VernacularTitle:替比夫定辅助治疗对乙型肝炎肝硬化患者血清IL-18、IL-12、IL-37及TNF-α水平的影响
- Author:
Jiantao LIU
;
Xu ZHANG
- Publication Type:Journal Article
- Keywords:
telbivudine;
HBV-related hepatocirrhosis;
interleukin-18;
interleukin-12;
interleukin-37;
tumor necrosis factor α
- From:
Chinese Journal of Biochemical Pharmaceutics
2015;(11):130-132
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effect of telbivudine on serum interleukin-18(IL-18),IL-12, IL-37 and tumor necrosis factor α(TNF-α) levels in patients with HBV-related hepatocirrhosis.Methods 66 cases of patients with HBV-related hepatocirrhosis were collected and divided into treatment group and control group according to the different treatment method , 34 cases in control group were treated with routine treatment , 32 cases in treatment group were treated by telbivudine on the basis of routine treatment.The serum IL-18, IL-12, IL-37, TNF-αlevels and adverse reactions were compared post-treatment.Results Compared with control group, the levels of IL-18, IL-12, IL-37 and TNF-αdecreased significantly post-treatment (P<0.05).The above levels were significantly lower in treatment group post-treatment than that in control group(P<0.05).Conclusion Telbivudine adjuvant therapy could suppress viral replication, and improve liver function and immune response in patients with HBV-related hepatocirrhosis.
